Clinical Trials Using Romiplostim

Clinical trials are research studies that involve people. The clinical trials on this list are studying Romiplostim. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • Using Romiplostim to Treat Low Platelet Counts following Chemotherapy and Stem Cell Transplant in Patients with Blood Cancer

    This phase II trial investigates how well romiplostim works in treating low platelet counts following chemotherapy and stem cell transplant in patients with blood cancer. Platelets are made when the liver produces a hormone that travels to the bone marrow. Once the hormone is in the bone marrow, it finds a specific protein on the surface of cells called megakaryocytes. Megakaryocytes are responsible for making platelets. The more this hormone binds to the megakaryocytes, the more platelets are made. Romiplostim acts like the hormone produced in the liver because it finds the same proteins on the surface of megakaryocytes and helps increase the production of platelets. Romiplostim may be able to stimulate the cells in bone marrow to make more platelets in the blood, which may decrease the amount of platelet transfusions needed during hospital admission.
    Location: 3 locations

  • Romiplostim for the Treatment of Inherited and Acquired Disorders of Hematopoietic Failure

    This early phase I trial investigates the side effects of romiplostim and to see how well it works in treating patients with inherited and acquired disorders of hematopoietic failure. Bone marrow failure results when stem cells in the bone marrow stop making blood cells and the bone fails to do its job of making blood cells. Romiplostim works to stimulate the stem cells in the bone marrow which have stopped making blood cells (hematopoietic failure). Giving romiplostim may work better to improve bone marrow cell production and improve clinical symptoms in patients with inherited and acquired disorders of hematopoietic failure.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

    Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio